SLDB - Solid Biosciences Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Solid Biosciences Inc.

141 Portland Street
Fifth Floor
Cambridge, MA 02139
United States

IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees111

Key Executives

NameTitlePayExercisedYear Born
Dr. Andrey Juan Zarur Ph.D.Co-Founder & Chairman of Directors225kN/A1971
Mr. Ilan GanotCo-founder, Pres, CEO & Director697.5kN/A1974
Mr. Pedro Alvaro AmorrortuChief Operating Officer462kN/A1972
Dr. Carl Ashley MorrisChief Scientific Officer448kN/A1970
Dr. Andrey Zarur Ph.D.Co-Founder & Chairman of DirectorsN/AN/A1971
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Solid Biosciences Inc., a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a monoclonal antibody that is in preclinical trials to reduce fibrosis and inflammation. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits to DMD patients. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Solid Biosciences Inc.’s ISS Governance QualityScore as of July 29, 2019 is 10. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.